We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | NASDAQ:BIIB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.04 | 2.98% | 208.50 | 208.50 | 209.65 | 210.83 | 199.10 | 201.22 | 1,894,099 | 01:00:00 |
From Apr 2019 to Apr 2024
By Kim Richters
Merck KGaA said Tuesday that is reversing a 365 million euros ($425.8 million) provision for patent dispute proceedings in the U.S.
The provision relates to a patent dispute of its subsidiary EMD Serono Inc. with Biogen Inc. about Merck's product Rebif.
Merck said its decision comes after the U.S. Court of Appeals for the Federal Circuit ruled in favor of the German pharmaceutical-and-chemical company on Monday.
Merck added that it might book a provision of up to a mid- to high-double-digit million amount and will adjust its outlook accordingly.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
September 29, 2020 12:57 ET (16:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Biogen Chart |
1 Month Biogen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
